
Novo Nordisk A/S NVO
€ 31.56
0.18%
Geschäftsbericht 2025
hinzugefügt 14.03.2026
Novo Nordisk A/S Langfristiger Schuldenstrom 2011-2026 | NVO
Langfristiger Schuldenstrom Jährlich Novo Nordisk A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.34 B | 1.34 B | 1.17 B | 986 M | 822 M | 775 M | - | - | - | - | - | - | - | - | - |
Alle Zahlen in DKK-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.34 B | 775 M | 1.07 B |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Amarin Corporation plc
AMRN
|
2.15 M | $ 14.67 | -0.07 % | $ 6.09 B | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Cabaletta Bio
CABA
|
3.46 M | $ 2.82 | 1.44 % | $ 283 M | ||
|
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
5.05 M | $ 1.29 | -3.01 % | $ 329 M | ||
|
CEL-SCI Corporation
CVM
|
227 K | $ 3.47 | -1.7 % | $ 221 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
Denali Therapeutics
DNLI
|
8.31 M | $ 19.74 | -12.17 % | $ 3.25 B | ||
|
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | ||
|
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Equillium
EQ
|
363 K | $ 2.06 | - | $ 118 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 2.85 | 3.26 % | $ 592 M | ||
|
Eton Pharmaceuticals
ETON
|
65 K | $ 23.45 | -1.64 % | $ 631 M | ||
|
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | ||
|
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 47.55 | 0.98 % | $ 4.28 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
547 K | $ 4.45 | -1.77 % | $ 853 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M |